Chongqing Taiji Industry Group Co Ltd banner
C

Chongqing Taiji Industry Group Co Ltd
SSE:600129

Watchlist Manager
Chongqing Taiji Industry Group Co Ltd
SSE:600129
Watchlist
Price: 15.56 CNY Market Closed
Market Cap: ¥8.6B

P/FCFE

19.3
Current
68%
Cheaper
vs 3-y average of 60.3

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
19.3
=
Market Cap
¥9B
/
Free Cash Flow to Equity
¥444m

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
19.3
=
Market Cap
¥9B
/
Free Cash Flow to Equity
¥444m

Valuation Scenarios

Chongqing Taiji Industry Group Co Ltd is trading below its 3-year average

If P/FCFE returns to its 3-Year Average (60.3), the stock would be worth ¥48.56 (212% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+212%
Average Upside
94%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 19.3 ¥15.56
0%
3-Year Average 60.3 ¥48.56
+212%
5-Year Average 27.2 ¥21.92
+41%
Industry Average 35.7 ¥28.75
+85%
Country Average 26.4 ¥21.25
+37%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
CN
Chongqing Taiji Industry Group Co Ltd
SSE:600129
8.6B CNY 19.3 71.2
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 61.3 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 21 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 27.5 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 36.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 9.4 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 12.2 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD -766.6 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 24.3 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 24.3 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD 37.8 4 516.9

Market Distribution

In line with most companies in China
Percentile
41th
Based on 5 086 companies
41th percentile
19.3
Low
0.2 — 13.7
Typical Range
13.7 — 52.8
High
52.8 —
Distribution Statistics
China
Min 0.2
30th Percentile 13.7
Median 26.4
70th Percentile 52.8
Max 2 279 450.9

Chongqing Taiji Industry Group Co Ltd
Glance View

Market Cap
8.6B CNY
Industry
Pharmaceuticals

Amidst the sprawling urban landscape of Chongqing, a city often enveloped in a mystical cloak of fog, stands Chongqing Taiji Industry Group Co Ltd., a distinguished entity in the realm of pharmaceuticals. Commanding a legacy that spans over a century, Taiji Industry has mastered the delicate fusion of traditional Chinese medicine with modern pharmaceutical processes. This synthesis has propelled the company to the forefront of China's healthcare sector. The company’s operations revolve around robust research and development, manufacturing, and distribution, focusing on a diverse array of pharmaceutical products, health supplements, and TCM (Traditional Chinese Medicine) remedies. Seamlessly integrating innovation with traditional wisdom, the group has built an extensive portfolio catering to a wide range of medical needs, from cardiovascular treatments to neurological supports. Financially, Taiji Industry's prowess is underpinned by its diverse revenue streams, primarily flowing from its broad spectrum of medicinal drugs and health products. The company has capitalized on its established brand and extensive distribution networks, which span across the vast Chinese landscape and extend their reach into international markets. Their stronghold in distribution is further solidified by strategic collaborations with healthcare providers and retail pharmacy chains, ensuring reliable market penetration and accessibility to the end consumer. This well-oiled machine not only secures Taiji's position as a major pharmaceutical player but also drives its financial growth, allowing the company to invest continuously in innovation, quality enhancement, and market expansion. The synergistic blend of tradition and modernity continues to propel Taiji Industry through the ever-evolving pharmaceutical landscape.

Intrinsic Value
22.89 CNY
Undervaluation 32%
Intrinsic Value
Price ¥15.56
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett